Delphi Diagnostics was founded with the mission to advance personalized breast cancer therapy through innovative gene expression algorithms. Their core product, the Endocrine Activity Index, measures potential disease progression in patients with hormone receptor-positive, HER2-negative breast cancer undergoing endocrine therapy. By providing insights beyond conventional diagnostic tests, Delphi aims to enhance treatment decisions and improve patient outcomes in the oncology market.
Notable figures affiliated with Delphi Diagnostics include leading scientists and medical professionals on their board of directors and advisory board. The company has secured intellectual property rights for its Endocrine Activity Index technology, underscoring its innovative approach. Delphi's impact is marked by its contribution to more personalized and effective breast cancer treatments, addressing a critical need in oncology care.
